Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Publicacions (34) Publicacions de Jose Luis Alonso Romero
2024
2023
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041
-
Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia
Advances in Laboratory Medicine, Vol. 4, Núm. 3, pp. 279-287
-
Variantes genéticas recurrentes y priorización de variantes de significado clínico desconocido asociadas al síndrome de cáncer de mama y ovario hereditario en familias de la Región de Murcia
Advances in Laboratory Medicine, Vol. 4, Núm. 3, pp. 288-297
2022
-
Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact
BMC Health Services Research, Vol. 22, Núm. 1
-
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Lung Cancer, Vol. 173, pp. 83-93
-
Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance
European Journal of Medical Genetics, Vol. 65, Núm. 4
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1
-
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 6, pp. 1107-1116
2021
-
Analysis of adolescent oncology cases from 2008 through 2018 in a tertiary-level hospital: An opportunity for improvement
Future Oncology, Vol. 17, Núm. 12, pp. 1545-1551
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
-
Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study
Cancers, Vol. 13, Núm. 21
2020
-
Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy
Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 852-859
-
Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies
Critical Reviews in Clinical Laboratory Sciences, Vol. 57, Núm. 7, pp. 432-443
-
Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies
Hernia, Vol. 24, Núm. 2, pp. 257-263
2019
-
Prevalencia de factores ambientales, hormonales y reproductivos de riesgo asociados al cáncer de mama en una población en estadio precoz
IV Jornadas Doctorales Escuela Internacional de Doctorado de la Universidad de Murcia (Eidum)
2018
-
Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain)
European Journal of Medical Genetics, Vol. 61, Núm. 6, pp. 355-361
-
New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer
Cancer Genetics, Vol. 228-229, pp. 1-4
-
SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression
Frontiers in Endocrinology, Vol. 9